HbL PharmaConsulting, 9648 Olive Boulevard, #309, St. Louis, MO 63132, USA.
Expert Rev Clin Pharmacol. 2014 Jan;7(1):5-8. doi: 10.1586/17512433.2014.864949. Epub 2013 Nov 26.
Zolpidem and other non-benzodiazepine (BZD) hypnotic agents have become preferred drugs to manage insomnia. They are widely used among older adults because of perceived improved safety profiles compared with traditional BZDs. Accumulating data in recent years in patients over the age of 65, however, shed light on possible safety concerns of these medications and zolpidem specifically. Recent information regarding potential for excessive blood concentrations, effects on balance and memory and fracture risk data briefly is described. Clinicians should be aware of these most recent data. Non-drug therapies, as recommended in clinical guidelines, should be fully utilized for managing insomnia. Until better studies or pharmacovigilance data become available to guide patient selection for prescribing zolpidem and other non-BZDs, judicious use of these hypnotic agents in older adults is warranted.
唑吡坦和其他非苯二氮䓬类（BZD）催眠药物已成为治疗失眠的首选药物。由于与传统 BZD 相比，它们具有更好的安全性，因此在老年人中广泛使用。然而，近年来在 65 岁以上患者中的积累数据揭示了这些药物，特别是唑吡坦的可能安全性问题。最近有关潜在的血液浓度过高、对平衡和记忆的影响以及骨折风险数据的信息简要描述。临床医生应该了解这些最新数据。应充分利用临床指南推荐的非药物疗法来治疗失眠。在获得更好的研究或药物警戒数据来指导唑吡坦和其他非 BZD 的患者选择之前，明智地使用这些催眠药物是有必要的。
